Stockwinners Market Radar for April 17, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:17 EDT CF Industries and JERA enter joint development agreement on Louisiana facility - CF Industries and JERA Co., Inc., Japan's largest energy company, "announced that they have executed a joint development agreement, or JDA, to explore the development of greenfield low-carbon ammonia production capacity at CF Industries' Blue Point Complex in Louisiana. The JDA will guide JERA and CF Industries' evaluation of a joint venture agreement to build an approximately 1.4 million metric ton capacity low-carbon ammonia plant. JERA is contemplating a 48% ownership stake in the project as well as an agreement to procure more than 500,000 metric tons of low-carbon ammonia annually to meet demand for low-carbon fuels in Japan. JERA and CF Industries previously had signed a memorandum of understanding to explore a potential joint project development and sales and purchase of low-carbon ammonia. JERA and CF Industries aim to reach a final investment decision on the proposed project within a year for commencing production in 2028."

19:50 EDT Beneficient trading halted, news pending

18:09 EDT California Water Service districts treating for chromium-6 - California Water Service confirmed that its water systems will meet the new state maximum contaminant level of 10 parts per billion for chromium-6, which was adopted today by the State Water Resources Control Board. Cal Water developed and installed treatment for the contaminant in its impacted water systems in Dixon, Oak Hills (Salinas), Las Lomas (Salinas), and Willows when the same chromium-6 MCL, which was subsequently vacated for administrative reasons, was originally set in 2014. In fact, Cal Water's treatment system design was used as a model for other water utilities. After the MCL was vacated, Cal Water continued to treat those wells to protect customer health and safety. Cal Water plans to install treatment at a newer well that was brought online in Oak Hills, as well as at another well in Dixon that currently does not serve customers but could, if needed, within the two- to four-year compliance timeline. All other active wells above the MCL in these service areas are already being treated. "We take our responsibility to protect our customers' health and safety very seriously; that's why we continued to treat impacted water systems after the chromium-6 MCL was temporarily vacated," said Martin A. Kropelnicki, Cal Water Chairman & CEO. "We remain committed to meeting all state and federal standards set to protect public health and safety."

17:33 EDT Allison Transmission expands partnership with SANY - Allison Transmission partnered with SANY, a global heavy equipment manufacturer for the mining and construction markets, to integrate the Allison 4970 Specialty Series transmission into SANY's STC5000 500-ton all-terrain crane. These new cranes will be in operation in remote areas of China including the desert and mountain terrain. "Our off-highway vehicles require a powerful transmission designed to meet the challenge of navigating difficult terrain," said Du Jian, R&D Director of Crane Chassis, SANY. "We selected the Allison 4970 SP due to its proven ability to increase vehicle productivity and maneuverability." In addition to SANY's STC5000 crane, Allison is also the propulsion solution provider for the company's SAC600E 60-ton crane.

17:25 EDT Broad Capital Acquisition confirms funding to extend period for combination - Broad Capital Acquisition caused to be deposited $60K into the company's trust account for its public stockholders, representing 3.5c per public share, allowing the company to extend the period of time it has to consummate its initial business combination to May 13. The Monthly Extension is the fourth of the twelve monthly extensions permitted under the Company's Amended and Restated Certificate of Incorporation, as amended to date. On January 18, 2023, the company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement with Openmarkets Group, an Australian proprietary limited company, BMYG OMG Pty, an Australian proprietary limited company, and Broad Capital, a Delaware limited liability company, solely in its capacity as the company's sponsor, pursuant to which the company will enact its initial business combination.

17:19 EDT Duolingo to replace Cable One in S&P 400 at open on 4/22

17:02 EDT SilverCrest recovered 2.58M silver equivalent ounces in Q1 - N. Eric Fier, CEO, commented, "Our first quarter has set the stage for another year of strong operational performance at Las Chispas, with silver sales exceeding plan and positioning us well to achieve 2024 sales guidance. Mobilization of our new mining contractor began in February 2024 and ramp-up of the underground continues to progress well. In the quarter, we achieved record silver equivalent process grades of 874 grams per tonne and recoveries of 98.3%, while completing planned maintenance ahead of schedule and returning plant availability to 92% in March."

16:59 EDT Bank OZK jumps over 3% after reporting Q1 profit ahead of estimates - Shares are currently trading up over 3% to $43.13 in late day trading after first quarter earnings per share came in ahead of analyst estimates.

16:51 EDT Adtran to close Greifswald facility within three months - In a regulatory filing, the company stated: "As ADTRAN previously reported in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and Annual Report on Form 10-K for the year ended December 31, 2023, on November 6, 2023, the Company's management resolved to implement a comprehensive business efficiency program which includes site consolidations. In connection with the Business Efficiency Program, management of the Company determined on April 11, 2024 to close the Company's facility in Greifswald, Germany, within the next three months. The Company currently expects to incur total costs ranging from approximately $13.5 million to $18.4 million in connection with the closure of the facility. This includes cash charges ranging between approximately $13.3 million and $17.6 million in severance, outplacement and related expenses and a range of approximately $0.7 million to $1.3 million in lease exit costs, as well as non-cash charges of approximately $0.2 million in accelerated depreciation expenses. The Company expects these charges to be fully incurred in fiscal year 2024 with cash payments expected to span into 2025. The total estimated costs of the Business Efficiency Program are being adjusted accordingly. The Company does not currently anticipate incurring other charges or cash expenditures associated with the closure of the Facility. However, the Company will amend this disclosure in the event that there is a material change in costs or cash payments in connection with the closure of the Facility. The closure of the Facility will be substantially completed by June 30, 2024."

16:36 EDT Thoughtworks acquires technology assets, individuals from Watchful - Thoughtworks announced the successful acquisition of the individuals and technology assets from Watchful, a San Francisco headquartered company who helps organizations accelerate the creation, enhancement and deployment of AI models. This acquisition is a cornerstone in Thoughtworks' strategy to become the leading AI transformation partner globally. Thoughtworks has acquired a team of seven skilled professionals from Watchful, including the co-founders Shayan Mohanty and John Singleton. These individuals bring a wealth of AI and data expertise in addition to cutting edge AI research, which will enhance Thoughtworks' ability to deliver transformative AI and data solutions for clients. As Thoughtworks has acquired key personnel and assets from Watchful, the existing business operations of Watchful will cease. Current Watchful clients will continue to receive support for their existing subscriptions.

16:31 EDT Camden Property names Jessett president and CFO - Camden Property Trust announced its Board of Trust Managers has appointed D. Keith Oden from Executive Vice Chairman of the Board and President to Executive Vice Chairman of the Board, and Alex J. Jessett from Executive Vice President-Chief Financial Officer to President and Chief Financial Officer. Mr. Oden will retain his current role of providing strategic leadership and communicating and implementing the Company's mission. Mr. Jessett will continue to report to Mr. Oden and will retain his current responsibilities for overseeing the Company's financial, legal, real estate investment, and construction related functions, and will now also oversee the Company's operational functions. Additionally, the Board of Trust Manager has appointed Ben Fraker from Vice President-Finance and Treasurer to Senior Vice President-Finance and Treasurer. "These changes are part of good corporate governance and long-term succession planning, and recognize Alex's long-term contributions to Camden's success," said Richard J. Campo, Camden's Chairman and CEO.

16:20 EDT Discover reports Q1 net interest margin 11.03% vs. 11.34% last year - The company states: "Net interest margin was 11.03%, down 31 basis points versus the prior year. Card yield was 15.79%, up 73 basis points from the prior year primarily driven by higher prime rate and lower payment rates, partially offset by higher interest charge-offs. Interest expense as a percent of total loans increased 120 basis points from the prior year period, primarily driven by higher funding costs. The total net charge-off rate of 4.92% was 220 basis points higher versus the prior year period reflecting continued seasoning of recent vintages with higher delinquency trends. The credit card net charge-off rate was 5.66%, up 256 basis points from the prior year period and up 98 basis points from the prior quarter. The 30+ day delinquency rate for credit card loans was 3.83%, up 107 basis points year-over-year and down 4 basis points from the prior quarter. The student loan net charge-off rate was 1.58%, up 54 basis points from the prior year and up 6 basis points from the prior quarter. Personal loans net charge-off rate of 4.02% was up 208 basis points from the prior year and up 63 basis points from the prior quarter. Provision for credit losses of $1.5 billion increased $395 million from the prior year quarter driven by an $806 million increase in net-charge offs partially offset by a $410 million lower reserve build."

16:15 EDT Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP - Vigil Neuroscience announced the presentation of multiple oral and poster presentations on the company's lead clinical candidate iluzanebart at the 2024 American Academy of Neurology AAN Annual Meeting. "We are excited to see our enthusiasm for iluzanebart matched by clinical leaders in the ALSP community. The interim findings from both the IGNITE Phase 2 and ILLUMINATE Natural History studies support the potential of iluzanebart to become the first, disease-modifying therapy for those living with ALSP," said Petra Kaufmann, M.D., F.A.A.N, Chief Medical Officer of Vigil. "Both trials have led to an incredible step forward - not only in understanding ALSP disease progression, but also in drawing parallels between biomarkers and correlating clinical outcomes. "Vigil's interim IGNITE data demonstrated that iluzanebart was well-tolerated, and the data suggest a favorable impact on the protein product of the CSF1R gene whose dysfunction is the causal driver of ALSP," said Zbigniew Wszolek, M.D., consultant in the Department of Neurology at the Mayo Clinic. "Positive trends on MRI measurements support slowing in irreversible neurodegeneration, and to see these signals in patients as early as six months is very encouraging."..."The findings from ILLUMINATE highlight sensitive markers of ALSP pathophysiology that have the potential to provide valuable insight into clinical endpoints and improve the overall understanding of ALSP disease progression to inform future study designs," said David Lynch, Ph.D., Honorary Research Fellow, Department of Neuromuscular Diseases, University College London.

16:15 EDT Alcoa sees $20M impact in Q2 for Alumina segment adjusted EBITDA - The company states: "Within second quarter 2024 Alumina Segment Adjusted EBITDA, the Company expects sequential unfavorable impacts of $20 million related to higher seasonal maintenance and other mining costs for the Australia operations. Within second quarter 2024 Aluminum Segment Adjusted EBITDA, the Company expects favorable raw material prices and production costs to be fully offset by higher energy costs. Alumina costs in the Aluminum segment are expected to be unfavorable by $15 million sequentially."

16:13 EDT Alcoa reports Q1 Alumina production down 4% from Q4 - The company states: "Alumina production decreased 4% sequentially to 2.67M metric tons on lower production from the Australia refineries. In Aluminum, Alcoa produced 542,000 metric tons, consistent with the fourth quarter's strong output. In the Alumina segment, third-party shipments of alumina increased 6 percent sequentially primarily due to increased trading. In Aluminum, total shipments decreased 1% sequentially."

16:09 EDT DiaMedica Therapeutics says first patient dosed in relaunch of DM199 trial - The company states: "DiaMedica Therapeutics announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke. The company continues to work closely with its contract research organization, on re-engaging with study sites for the ReMEDy2 Trial. The trial is intended to enroll approximately 350 patients at up to 100 sites globally. The majority of the U.S. sites are expected to be activated by the end of the third quarter of 2024. With the support of the Canadian Stroke Consortium, the activation of study sites in Canada is expected to begin in the third quarter of 2024. In Australia, the Company has received provisional endorsement from the Australian Stroke Trials Network and Australian site activation is expected to commence in the fourth quarter of 2024. Initial steps are also being taken to expand ReMEDy2 into the United Kingdom, Spain, and select other European countries."

16:08 EDT Las Vegas Sands reports Q1 consolidated adjusted property EBITDA $1.21B - Reports Marina Bay Sands adjusted property EBITDA of $597M.

16:07 EDT PRA Group appoints Steve Macke as Global Operations Officer - PRA Group has named Steve Macke as its global operations officer, effective April 29, following an external search. Macke joined Citi in 1991 as a collector and rose through the leadership ranks, having most recently served as managing director and global head of contact centers. Previously, he was managing director and global head of collections and default management, as well as managing director and global head of workforce management.

16:06 EDT Evolus discloses publication of Phase 2 study data of 40U Jeuveau - The company states: "Evolus announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau(R) (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The "extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau(R) Extra-Strength 40U and two active controls, BOTOX(R) 20U and Jeuveau(R) 20U. Efficacy results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale. The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified."

16:01 EDT Wabtec secures systems, software deal with ARTC - Wabtec Corporation announced a digital solutions agreement with Australian Rail Track Corporation. The two companies will collaborate on developing one of the few approaches being considered to address interoperability of rail systems in Australia. The company will investigate the capabilities of ARTC's Advanced Train Management System solution. Wabtec will develop the interoperability standard between ATMS and European Rail Traffic Management System Level 2. ARTC and Wabtec will work together with the relevant stakeholders to outline the concept of operations and define the standards to realize the interoperability solution. "ARTC recognizes the complex challenge of solving interoperability, and we are pursuing multiple pathways to find a feasible solution that will help to make rail safer and more competitive across Australia. We are excited to partner with Wabtec to actively pursue one of the options," said Wayne Johnson, CEO and Managing Director of ARTC. "Wabtec was selected to support this project as a rail industry leader with a proven track record of implementing a safety critical train control solution for the entire freight network in the United States spanning over 100,000kms and 21,000+ locomotives. The Australian Government recognizes the importance of rail interoperability as a priority, and we will continue to work with government and other key stakeholders to deliver systems and software solutions that enhance the nation's rail system."

14:32 EDT Boston Scientific recalls 1,594 Obsidio Embolic devices in U.S. - Boston Scientific Corporation is recalling 1,594 Obsidio Embolic devices in the U.S. by issuing a correction, according to a post from the FDA. An investigation determined that delivery of Obsidio Embolic using the aliquot technique, a commonly used delivery method in embolization procedures, for lower gastrointestinal bleeding embolization poses a high risk of bowel ischemia. The most serious and the most common adverse health consequence is the need to perform major surgery such as bowel resection and/or diverting colostomy. Use of this product with the aliquot technique may prevent blood and oxygen flow to organs including the small bowel or non-target embolization, all of which may lead to prolonged hospitalization, the need for additional surgery or death. Boston Scientific does not recommend that the aliquot technique be used to deliver Obsidio Embolic for lower GI bleed embolization procedures. There were 11 incidents reported, seven injuries, and two deaths related to this issue. Reference Link

13:24 EDT Zuora trading resumes

13:21 EDT LightPath granted European Defense manufacturing license - LightPath Technologies has received a European Defense license, which provides the Company with the ability to supply products to the European Defense industry, one of the largest defense markets in the world.

12:00 EDT CoreCard rises 7.7% - CoreCard is up 7.7%, or $1.01 to $14.15.

12:00 EDT ADC Therapeutics rises 10.6% - ADC Therapeutics is up 10.6%, or 47c to $4.91.

12:00 EDT Travelers falls -7.9% - Travelers is down -7.9%, or -$17.73 to $205.38.

11:52 EDT Publicis proposes change to governance structure - Publicis Groupe announced a proposed change to the company's governance, that will be put to a shareholder vote at its Annual General Meeting on May 29. "Publicis has undergone a period of sustained momentum over the past years, thanks to its unique model adapted to the needs of some of the world's leading companies, its unmatched capabilities and the depth of its talent bench. To further support that dynamic, and the leadership teams behind it, and in anticipation of the end of his mandate in 2025, Maurice Levy, Chairman of the Supervisory Board, submitted to the Groupe's governing bodies a proposal to change the company's governance. This change would see the company shift from a dual structure corporation with a Supervisory Board and Management Board, and instead adopt the more widespread model of a single structure corporation with a Board of Directors. Following a lengthy and rigorous process, the Supervisory Board unanimously approved the proposal, which will be subject to a vote by shareholders during the upcoming Annual General Meeting. In this new structure, Arthur Sadoun would become Chairman and CEO of the Board. His appointment would be accompanied by the creation of the role of Lead Director, and the reinforcement of the Board's committees, as part of a well-balanced governance model and in line with AFEP-MEDEF guidelines. Maurice Levy, Chairman of the Supervisory Board, would be named Chairman Emeritus in order for the Groupe to continue to benefit from his insight, experience, and leadership. In addition to attending board meetings, Maurice Levy would preside over a mixed group of board members and executives, with a clear focus on innovation and foresight. These changes would allow for the continuation of the partnership formed by Levy and Sadoun, which in the past seven years has seen Publicis become first in the industry on market capitalization," the company stated.

11:38 EDT FAA approves ground stop for Alaska Air, Horizon flights - The FAA approved a ground stop for all Alaska and Horizon flights starting at approximately 10:50 a.m. ET. Reference Link

11:11 EDT Custom Truck One Source acquires business of A&D Maintenance and Repair - Custom Truck One Source announces its acquisition of the business of A&D Maintenance and Repair. Founded in 1986, A&D Maintenance is a family-owned, full-service repair facility located in Wyandanch, New York on Long Island. This acquisition adds over 20,000 square feet of space and a highly experienced team that significantly expands Custom Truck's presence and service capacity on Long Island and in the greater New York City metro area. The new Wyandanch branch is poised to offer the full breadth of Custom Truck's product offering, as well as repair services, to customers in the region.

10:55 EDT United Airlines: Working to reduce costs

10:51 EDT Sonoco Products increases quarterly dividend to 52c per share - The Board of Directors of Sonoco increased its quarterly common stock dividend to 52c per share from the previous quarterly distribution of 51c per share. This new dividend will be paid on June 10, 2024, to shareholders of record as of May 10, 2024. With this increase, Sonoco's annualized dividend payout moves to $2.08 per share. Future quarterly declarations and the establishment of future record and payment dates are subject to final determination by Sonoco's Board of Directors.

10:45 EDT United Airlines likes macro setup for 2H24

10:37 EDT United: Certain certifications to be delayed working through FAA review

10:36 EDT United Airlines has started in depth review of process and procedures with FAA - Comments taken from Q1 earnings conference call.

10:25 EDT Vanda adopts limited duration stockholder rights plan - Vanda Pharmaceuticals announced that its board of directors has adopted a limited duration stockholder rights plan to "protect stockholder interests and maximize value for all stockholders." The rights plan is effective immediately. "The board adopted the rights plan in response to the unsolicited acquisition proposal made by Future Pak on April 1, 2024. The board, in consultation with its independent financial and legal advisors, consistent with its fiduciary duties, carefully reviewed the unsolicited acquisition proposal and concluded that it is not in the best interests of the company and its stockholders, as it significantly undervalues the company in light of its robust clinical development pipeline, expanding commercial presence, significant cash balance and long-term future growth prospects. The rights plan is intended to enable stockholders to realize the full value of their investment in Vanda and will reduce the likelihood that any entity, person or group gains control of the company through open-market accumulation without paying all stockholders an appropriate control premium or providing the board sufficient opportunity to make informed judgments and take actions that are in the best interests of all stockholders. The rights plan applies equally to all current and future stockholders and is not intended to deter offers or preclude the board from considering offers that are fair and otherwise in the best interest of the company's stockholders. The rights plan is similar to other plans adopted by publicly held companies in comparable circumstances. Under the rights plan, the rights will become exercisable if any person, entity or group acquires beneficial ownership of 10% or more of Vanda's outstanding common stock in a transaction not approved by the board. In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder (other than the person, entity or group triggering the rights plan, whose rights will become void and will not be exercisable) to purchase, at the then-current exercise price, additional shares of common stock or equivalent securities having a then-current market value of twice the exercise price of the right. The rights plan has a one-year term, expiring on April 16, 2025. The board may consider an earlier termination of the rights plan as circumstances warrant. The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29," the company stated.

10:22 EDT Winmark increases regular quarterly cash dividend to 90c from 80c per share - Winmark announced that its board of directors has approved an increase in its regular quarterly cash dividend to shareholders. The quarterly dividend of 90c per share represents an increase of 10c from its previous dividend rate. The cash dividend will be paid June 3 to shareholders of record on the close of business on May 15.

10:17 EDT Summit Wireless Technologies trading halted, volatility trading pause

10:04 EDT Generations Federal Credit Union partners with Q2 Holdings - Q2 Holdings announced that Generations Federal Credit Union has partnered with Q2 to offer a comprehensive suite of in-demand digital banking services and experiences. Generations FCU rapidly transformed its member experience by leveraging Q2's digital banking platform, Q2 Innovation Studio and Q2 Marketplace, which allows the credit union to integrate third-party fintech solutions seamlessly into its digital banking experience and offer innovative services directly to members.

10:03 EDT Momentus, Ascent Solar partner to bring to market solar arrays - Momentus (MNTS) and Ascent Solar Technologies (ASTI) announced a new partnership to jointly market solar arrays utilizing the low-cost Tape Spring Solar Array being developed by Momentus and the high performance of Ascent's photovoltaic modules. "TASSA is designed to generate extensive power at very low cost while minimizing mass and volume," said Rob Schwarz, Momentus CTO. "TASSA is intended to allow Smallsats to generate kilowatts of power on orbit without breaking their mass, thermal, or cost budgets. This design optimization also facilitates improved satellite packing efficiencies and allows constellations to be fielded quicker and cheaper."

10:02 EDT Constellation seeks license to operate Dresden center for additional 20 years - Constellation announced that it has filed a subsequent license renewal application with the Nuclear Regulatory Commission for its Dresden Clean Energy Center in Morris, Illinois. The facility's license was first renewed by the NRC in 2004. The filing begins a comprehensive, multi-year review by the NRC to renew the station's license, which, with adequate market or policy support, would allow it to continue providing Illinois with reliable, carbon-free energy for another 20 years through 2051. Dresden, which produces enough baseload, carbon-free electricity to power the equivalent of nearly 1.4 million homes, is currently licensed to operate through 2029 for Unit 2 and 2031 for Unit 3.

10:00 EDT Spirit Airlines rises 6.1% - Spirit Airlines is up 6.1%, or 25c to $4.36.

10:00 EDT CoreCard rises 10.5% - CoreCard is up 10.5%, or $1.39 to $14.53.

10:00 EDT Montrose Environmental falls -7.1% - Montrose Environmental is down -7.1%, or -$2.96 to $38.99.

09:50 EDT ICZOOM Group Inc trading resumes

09:47 EDT APi Group falls -5.3% - APi Group is down -5.3%, or -$2.09 to $37.02.

09:47 EDT Miniso rises 5.3% - Miniso is up 5.3%, or $1.00 to $20.02.

09:47 EDT Inspire Medical rises 6.0% - Inspire Medical is up 6.0%, or $13.28 to $234.91.

09:39 EDT Sunshine Biopharma Inc trading halted, volatility trading pause

09:21 EDT Kingstone Companies announces contract extension for CEO Meryl Golden - Kingstone Companies announced that its Board of Directors has agreed with Meryl Golden, CEO, to extend the term of her employment agreement another two years, through December 31, 2026. Ms. Golden's initial term was set to expire December 31, 2024.

09:18 EDT Guaranty Bancshares announces educational partnership with Texas A&M University - Guaranty Bank & Trust, N.A. is pleased to announce a groundbreaking academic partnership with Texas A&M University-Texarkana, aimed at fostering education and professional development for its full-time employees. This collaboration will facilitate the pursuit of accessible, quality education within the Texarkana community. Commencing on April 12 at the Texas A&M University-Texarkana campus, this partnership exemplifies Guaranty Bank & Trust's commitment to investing in the growth and advancement of its workforce. Through this initiative, full-time employees of the bank will have the opportunity to enroll in courses at Texas A&M University-Texarkana at a reduced cost, empowering them to pursue higher education without compromising their professional commitments

09:16 EDT Freight Technologies' Fr8App selected by Grupo Solave - Freight Technologies announces its appointment as Solave's logistics solutions provider for cross-border operations. Solave, recognized for its leadership in the Blue Agave market with achievements such as becoming a global leader in Agave Syrup production, a frontrunner in cultivating Blue Agave plants in Mexico, and a reputable Tequila producer for notable brands, aims to benefit from optimized logistics and supply chain efficiency through Fr8App's platform.

09:15 EDT Mitesco begins new data center, infrastructure initiative - Mack Leath, Chairman of the Board of Directors, provided the following update: "The year-end results are now complete, and while it was clearly a year focused on winding down the Company's healthcare subsidiary, "The Good Clinic," we also set the stage for new initiatives aimed at businesses that may find greater growth opportunities going forward. Our recently appointed Advisory Board staff has identified significant market entry points, with our first efforts beginning today, as noted below: This week marks a new beginning for the Company as we embark on an initiative using technology to address key infrastructure needs through data center services and application-specific software and staffing. Industry sources suggest that revenue in the data center market is projected to reach US$99.16bn in 2024, and that network infrastructure dominates the market with a projected market volume of US$42.87bn in 2024. Key data center trends of note include: expanded power and cooling needs, including new liquid cooling technologies; learning systems driving the increased need for greater access and bandwidth; and edge and cloud computing with highly secure and reliable network access. These needs drive new demand for power generation, both standalone and through optimized power grids. Smaller communities and utilities will be impacted, and their base of customers on whom they rely for revenue will drive them to invest quickly to meet demand. We believe all of these trends create opportunities for new initiatives. We intend to focus on markets that require highly secure network access and data security, both commercial and within the municipal and utilities markets. Smaller providers are being pressured to increase their security in defense of malicious actors, while at the same time increase monitoring capabilities at their facilities. Many of these providers do not have the in-house resources to facilitate staffing and systems. We therefore believe that offering outsourcing of both traditional systems and next generation cyber security may be an excellent entry point for this market. We are adding additional staff to our Advisory Board that includes senior executives who have spent their careers serving the commercial, governmental, and utility markets through Geographical Information Systems, law enforcement, and land planning and development software. This expertise should allow us to rapidly enter the market with minimal capital and create near immediate accretive results. We are continuing to reduce the overhang from previous investments in the healthcare arena. We have reduced the liabilities from previous facilities by 80% in some cases and have plans in development to preserve the investment of our common stock shareholders while allowing previous institutional investments to participate going forward."

09:11 EDT Hyperfine reports 1st AD patients enrolled in CARE PMR observational study - Hyperfine announced that the first patients have been enrolled in the CARE PMR or Capturing ARIA Risk Equitably with Portable MR, observational study. The study is designed to assess the clinical utility and workflow benefits of Swoop system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities, ARIA, in Alzheimer's patients receiving amyloid-targeting therapy at the times specified in the labeling..."The newly approved amyloid-targeting therapy represents a major milestone in the global fight against Alzheimer's, bringing hope of additional years of independent living to patients. The required MRI scans to image brain abnormalities in patients receiving amyloid-targeting therapy present workflow challenges for patients and providers," said Hyperfine, Inc. President and CEO Maria Sainz. "Patients can be safely scanned with the Swoop system wherever in a healthcare setting is most convenient, and we believe that it greatly simplifies the workflow and provides significant benefits in care efficiency and cost. We look forward to investigating its potential as a screening tool and exploring how this accessible and affordable portable MRI modality can help address the challenges of access to care and equity challenges intrinsic to new treatments for this devastating global disease."

09:11 EDT Wearable Devices announces latest updates for Mudra Band - Wearable Devices announced a significant breakthrough in digital interaction with the latest updates to the Mudra Band. At the heart of these updates is the introduction of a new AI gesture mouse for Mac computers, a feature set to redefine user interaction within the Apple ecosystem. The AI gesture mouse feature introduces an innovative way for users to interact with their Mac computers, transcending traditional input methods. Leveraging advanced AI and machine learning, Mudra Band now allows Mac users to experience natural, effortless scrolling and navigation through a simple "reverse-pinch" gesture, marking a new era of convenience and efficiency.

09:09 EDT LPL Financial: Legacy Retirement joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Phil Eggers of Legacy Retirement Planning has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported serving approximately $170 million in advisory, brokerage and retirement plan assets and joins LPL from Raymond James. Based in Plano, Texas, Eggers began his career as a financial advisor in 1990 and considers it an honor to manage the wealth for approximately 300 families. He works alongside of Operations Manager Matthew Ford, and they both firmly believe it's their responsibility to always put clients first in every decision.

09:09 EDT Safe and Green Development 'excited' to announce launch of Xene Home 'shortly' - Safe and Green Development provides an update and strategy regarding the operations of the business. CEO David Villarreal said, "On behalf of SG DevCo, I would like to present you a quarterly business update. We intend to provide you with an update like this shortly after the end of each fiscal quarter. As the Company evolves, we know it is important to communicate to our shareholders as often as possible. We would also like to provide clarity as to our ambitions for the upcoming year. Our real estate assets, as previously mentioned, have appreciated significantly since the time we purchased them. We will continue to be opportunistic and creative in our strategies to monetize our current asset base. The combined value of which, per our appraisals, is significantly above our current market cap. Although the macro-economic environment has created a more challenging landscape for real estate development, we remain committed to delivering as much value as possible from our asset base. We are very excited to announce the public launch of our Xene Home platform shortly. After considerable due diligence we have invested in this software and the associated AI tools to provide value to our subscriber members. This business is expected to generate recurring revenue throughout the second quarter. From this platform we anticipate being able to generate additional revenue streams through services such as home warranty, home insurance and mortgage financing. There is a clear alignment between the Xene Home platform and our future real estate development opportunities. We intend to use the Xene Home website and network to market our future projects and units. While we build this out, we will continue to keep an eye on the technological landscape and take advantage of future opportunities to increase our presence and foothold in the industry. The goal of this is to create a sustainable business with a solid asset base and diversified streams of revenue from both development and technology."

09:07 EDT ABVC BioPharma executes global licensing agreement for treatment of NSCLC - ABVC BioPharma announced that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1,250,000 in cash after OncoX's next round of fundraising, of which there can be no guarantee; ABVC and its affiliate are also entitled to royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product. Under the terms of the agreement, ABVC grants OncoX exclusive rights for one of ABVC's four products in its Oncology pipeline to develop, manufacture, and commercialize BLEX 404, a promising therapeutic agent for the treatment of Non-Small Cell Lung Cancer, NSCLC. We believe that this collaboration leverages the respective strengths of both companies to accelerate the availability of this vital treatment to patients worldwide. "We are thrilled to finalize this licensing agreement with OncoX, an emerging frontrunner in the healthcare industry," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "This collaboration represents a significant step forward in our mission to combat NSCLC and underscores our commitment to delivering innovative therapies to needy patients. "He added that ABVC brings its cutting-edge research and development capabilities. With a deep understanding of NSCLC and a commitment to improving patient outcomes, ABVC will spearhead the development of BLEX 404, which has demonstrated promising results in clinical studies."

09:06 EDT Taboola announces results of holiday advertising campaign with Bombas - Taboola announced the results of a successful holiday advertising campaign with Bombas, driving 300% Return On Ad Spend, ROAS, in November 2023. To drive success, Bombas used Taboola's Maximize Conversions, an automated bidding solution that enables advertisers to evolve beyond manual and time-consuming cost per click bidding optimizations, in favor of simply specifying a budget and having Taboola's algorithm automate the CPC bid to drive as many conversions as possible, while staying within budget. Through this, in Q4, Taboola was able to drive 224% total ROAS, 50% higher ROAS than the goal, and a $36 CPA, 49% lower than the goal. "Maximize Conversions continues to be used by top brands because it drives real advertiser success, and it's great to see more of our longtime partners, like Bombas, adopting it," said Adam Singolda, Founder and CEO of Taboola. "I'm excited about these results and Maximize Conversions being one of our most rapidly adopted offerings ever."

09:04 EDT Janover reports 766% increase in banking originator sign-ups on its platform - Janover announced that it achieved significant year-over-year growth in lenders on its fintech platform in 2023, providing borrowers with access to a broad range of competitive loan products. Key Highlights: 766% increase in banking originator sign ups; 647% increase in credit union originator sign ups; 445% increase in the 'other' category sign ups, including debt funds, private groups, life insurance companies, family offices, and REITs. Reflecting its strong market presence, Janover has achieved substantial penetration based on the FDIC active commercial banking and NCUA data as of December 31, 2023: 30% of all active FDIC-insured banks are on Janover's platform; Approximately 11% of all active FDIC-insured banks are now represented by a verified banker on Janover's platform; Over 6% of all active NCUA insured credit unions are on Janover's platform.

09:03 EDT PowerSchool falls 6% to $18.51 after Spruce Point short report

09:03 EDT Fat Brands announces co-branding strategy with 40-unit Northern California deal - FAT announces a new development deal to open 40 new franchised Fatburger locations across Northern California. In partnership with franchisee California Burger, Fatburger will be added to 40 existing Round Table Pizza locations over the next 10 years with the first location set to open in 2024. "Since opening our first co-branded Fatburger and Round Table Pizza in the Dallas area last year, we have seen significant interest in this pairing from our franchisee base," said Taylor Wiederhorn, Chief Development Officer of FAT Brands. "We are pleased to further the growth of this new co-branded model with California Burger, Inc. who also operates Circle Pizza LLC, the largest multi-unit operator of Round Table Pizza with over 70 Round Table Pizza restaurants in operation. We see great potential for Fatburger and Round Table Pizza co-branded restaurants given both brands' California heritage. The strategy is not unsimilar to the success we have experienced with co-branded locations of Fatburger and Buffalo's Express, which now number over 100 locations worldwide."

08:58 EDT Dominari Holdings continues expansion of Capital Markets Group - Dominari Holdings has further expanded its practice with the addition of Steve Kann and Andre Peschong as Managing Directors. Kann has more than 30 years of experience in corporate finance, buy and sell-side equity research, operations, marketing, consulting and has been a founder, advisor, agent, banker and investor in dozens of companies during his career. He has also served as a mentor for startup accelerators, AccelerateDC and Startup Grind NY. Peschong has more than 25 years of corporate finance, investment banking, senior management, business development and capital markets experience. He is currently the Chairman of the Board of Impossible Kicks, one of the largest brick and mortar sneaker resellers in the United States. He remains an active partner in Ocean Street Partners, a merchant banking and corporate advisory firm.

08:50 EDT Alcoa up 3% on reports Biden to propose higher Chinese steel, aluminum tariffs

08:44 EDT Lipella Pharmaceuticals expands Scientific Advisory Board - Lipella Pharmaceuticals announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine; and Pradeep Tyagi, PhD, MBA, Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Drs. Hafron and Tyagi have complementing expertise in both clinical and translational research in cancer treatment, with a focus on urologic oncology.

08:40 EDT ContextLogic urges stockholders to vote for Qoo10 transaction - ContextLogic reminds stockholders to vote "FOR" the proposed transaction with Qoo10 at the upcoming Special Meeting of Stockholders. The Special Meeting is scheduled to be held at 11:30 a.m. Pacific Time on April 18, 2024. Stockholders of record as of March 7, 2024, are entitled to vote.

08:39 EDT FireFly announces David DeCaprio to join board of directors - Firefly Neuroscience announces that David DeCaprio has entered into an agreement to join the Company's Board of Directors upon completion of the anticipated merger with WaveDancer. This appointment is a key step towards Firefly's anticipated start of trading on the NASDAQ. DeCaprio has significant experience transitioning advanced technology from academic research labs into successful businesses. He is a Co-founder of ClosedLoop.ai.

08:38 EDT Banzai, New to The Street sign 12-month media contract - FMW Media's New to The Street announces signing a twelve-month media contract with Banzai International. New to the Street will produce and film interviews with Banzai's key management, broadcast each segment on television, and provide social media marketing to further the reach of each broadcast. New to The Street's TV anchors will talk with Banzai's management team about the Company's digital marketing technology platforms focusing on "Engagement Marketing," giving its customers unique and effective sales and marketing solutions.

08:37 EDT IGM Biosciences announces refocusing of Sanofi collaboration - IGM Biosciences (IGMS) announced that the Company's exclusive worldwide collaboration agreement with Sanofi (SNY) to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration. As previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research and development activities and assume related costs through the completion of a Phase 1 clinical trial for up to two constructs directed to each target, after which Sanofi will be responsible for all future development and commercialization activities and associated costs. IGM will be eligible to receive up to $1,065 million in aggregate development, regulatory and commercial milestones per target as well as tiered high single-digit to low-teen royalties on global net sales.

08:36 EDT Outset Medical U.S. Renal Care in deal to expand U.S. home dialysis - Outset Medical announced a multi-year agreement to help accelerate home hemodialysis in the U.S. Studies show patients with end-stage kidney disease ESKD are healthier mentally and physically dialyzing at home, more likely to be employed and maintain more control of their daily activities. Yet, just 3% of the ESKD population currently performs home hemodialysis, in large part due to historically complicated systems that made it too difficult to undertake or sustain. Under the multi-year agreement, U.S. Renal Care can utilize Outset's Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care. Patients dialyzing with Tablo report that the system is easy to learn and operate in their home. Expanding treatment options in the communities served by U.S. Renal Care will aid in meeting the growing demand of dialysis patients seeking treatment at home. "Our collaboration with U.S Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyze." said Leslie Trigg, Chair and CEO of Outset Medical. "Tablo was specifically designed to reduce the complexity of dialysis and help restore the identity and agency of patients who must dialyze to survive. We are pleased to partner with U.S. Renal Care to advance this mission."

08:35 EDT Sportsman's Warehouse reduces board size from nine to six - Sportsman's Warehouse Holdings announced that Erica Fortune, Gregory Hickey and Philip Williamson have each notified the Board of Directors of their intention to resign as a member of the Board prior to the commencement of the Company's 2024 Annual Meeting of Stockholders. Upon the effectiveness of these resignations, the Board will reduce its size from nine to six members. Following these anticipated changes, half of the Company's Board will have been added within the past year.

08:34 EDT Elys BMG Group announces approval for The Ugly Mug Sportsbook - Elys BMG Group announces that The Ugly Mug in Washington D.C. has been granted provisional approval from the District of Columbia Office of Lottery and Gaming Regulation and Oversight Division to open its sportsbook at 723 8th St. SE. As the fourth privately owned sportsbook venue in the District powered by Elys' innovative Gameboard betting technology, The Ugly Mug stands as a testament to Elys' commitment to bringing cutting-edge solutions to local businesses and sports enthusiasts. The grand opening for The Ugly Mug sportsbook is anticipated to occur during the week of April 27th. Elys will unveil the grand opening festivities, promotions, and events as the date draws closer.

08:33 EDT Innovative Eyewear announces partnership with Windsor Eyes - Innovative Eyewear announced a new partnership with Windsor Eyes, a leading eyewear manufacturing and distribution firm. The partnership aims to forge a robust collaboration between Innovative Eyewear's unique, cutting-edge smart eyewear products and Windsor Eyes' well-established distribution network within the optical retail sector. Together, Innovative and Windsor intend to work closely to ensure extensive distribution of smart eyewear across the United States, targeting key large optical retail outlets.

08:23 EDT I3 Energy announces partial sale of royalty assets - i3 Energy announced that its subsidiary, i3 Energy Canada Ltd., has entered into a definitive agreement with a newly formed private royalty company for the sale of certain of the Company's royalty assets for a total gross cash consideration of $24.81 million before customary closing adjustments. The proceeds of the Royalty Disposition mark the next step in transitioning i3's capital structure, enhancing the Company's financial flexibility through improved liquidity and enabling acceleration of its growth and income-based business plan. The Royalty Disposition, involving most of the Company's royalty assets, but not its core Simonette Royalty, provides substantial capital and will allow i3 to accelerate value associated with its extensive inventory of high-return drilling locations, while jointly pursuing accretive inorganic growth initiatives. The Royalty Disposition is comprised of i3 fee royalties, i3 gross overriding royalties, along with certain newly created royalties on a minor subset of previously unburdened lands, and is expected to average 388 boe/d in 2024, while delivering $3.61 million in royalty income based on strip pricing. The Company now has a fully undrawn $55.56 million senior secured revolving credit facility with a Canadian chartered bank and will remain disciplined with its conservative approach to debt management as it looks to balance stable, predictable, growth, along with its ongoing dividend programme. The Company now looks forward to updating the market later this month with its capital programme for 2024.

08:20 EDT FSD Pharma expands pipeline to include weight loss, liver health formulations - FSD Pharma announced the expansion of its pipeline into metabolic and related disorders including weight loss and liver health. The Company has initiated investigations into ingredients and dietary supplements that may have the potential to promote weight loss and liver health. The Company is already pursuing products in to promote faster alcohol metabolism and ameliorate the effects of acute alcohol intoxication. The Company is investigating certain ingredients and combinations of ingredients that show promise in improving liver health, reducing metabolic disease, and reducing visceral fat which could lead to weight loss and liver health. The Company is pursuing this pipeline to potentially create a new exciting product line in addition to unbuzzd.

08:19 EDT Brera Holdings says football clubs in Asia, Africa resume seasons - Brera Holdings announced that its football clubs in Asia and Africa have resumed their seasons and are back in action with first-division status in both countries. After assuming control of Bayarzurkh Sporting Ilch FC, a team in the Mongolian National Premier League, Brera Holdings rebranded the club as Brera Ilch FC last October. After the season resumed, in early March 2024, with a new coaching and management staff, the team has 3 wins in 6 matches. Two key wins in the direct clashes against rival clubs, 8-1 vs Bavarians FC and 3-1 vs Khovd, fueled the comeback. Among the new players, Aoto Saito, a Japanese striker, has quickly rocketed to the top of the scoring table, with 10 goals in just six games. The football season in Mongolia will conclude early July. In Mozambique, Brera Tchumene, enters the new Mocambola season, with a team that features the coach and several key players who were instrumental in achieving promotion to the First Division, in the club's inaugural season. Brera Tchumene will make its full top flight debut against Desportivo de Nacala on Saturday, April 20. In the pre-season tournament the Torneio de Abertura - LigaJogabets, Brera Tchumene ranked second behind Desportivo da Matola. Brera Tchumene will, again, play in the modern facilities of Associacao Black Bulls. The season will end in November.

08:17 EDT Genetic Technologies to establish precision oncology division, diagnostic tests - Genetic Technologies announces the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists, helping determine which therapies will have the most efficacious impact in treating a range of cancers including melanoma, lung, pancreatic, colorectal, breast, ovarian and brain cancers. Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests. Earlier detection of a range of cancers leads to significantly improved patient outcomes. These new tests will transform oncology diagnostics, companion diagnostics, and disease monitoring. A guideline-driven approach for reimbursement makes tests accessible and affordable for patients.

08:15 EDT Bitcoin Depot signs Fareway Stores as its first major grocery chain - Bitcoin Depot announced its retail partnership with Fareway Stores, a growing Midwest grocery company currently operating more than 130 grocery store locations across the Midwestern US. Bitcoin Dept plans to deploy BTMs in 66 Fareway locations starting in Q2 of 2024, throughout Iowa, Illinois, Minnesota, Nebraska, South Dakota, Kansas, and Missouri. "We're thrilled to work with a growing grocery store brand like Fareway as we continue our own expansion efforts in 2024, reinforcing our commitment to providing easy and convenient crypto access to new and returning users," said Brandon Mintz, CEO of Bitcoin Depot. "Our technology has a proven track record of success across our portfolio of retail partners, and I believe our customer-first approach aligns perfectly with Fareway's ethos. We anticipate a mutually beneficial partnership that enhances the cash to Bitcoin experience for Fareway customers."

08:15 EDT Science 37 announces launch of Patient Recruitment Solution - Science 37 announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented. While traditional central patient recruitment campaigns have proven to be effective in accelerating enrollment, they are fraught with inefficiencies. "We've been recruiting, qualifying, and consenting patients for 10 years as a Metasite," said Erica Prowisor, SVP of Patient & Provider Networks at Science 37. "We empathize with sites on the complexity required to turn a referral into a consented participant. Today, we're offering sponsors the opportunity to relieve sites of that burden, ensure their recruitment spend is more efficient, and meet their ultimate goal of accelerated enrollment."

08:13 EDT Golden Sun Education Group announces 1-for-10 share consolidation - Golden Sun Health Technology announced that the shareholders of the Company had approved a proposed 1-for-10 share consolidation of the Company's ordinary shares at an extraordinary general meeting of shareholders held on April 11, 2024, at 8th Floor, Administration Building, 390 East Tiyuhui Road, Hongkou District, Shanghai, China. At the opening of trading on April 19, 2024, the Company's class A ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Stock Market under the same symbol "GSUN", but under a new CUSIP number of G4013A115. The primary objective of the Share Consolidation is to enable the Company to regain compliance with Nasdaq Listing Rule 5550(a)(2) relating to the minimum bid price per share of the Company's Class A ordinary shares.

08:11 EDT Zapata AI announces $1M commercial expansion under agreement with Andretti - Zapata AI announced a $1,000,000 commercial expansion, entered into on March 28, 2024, under its existing agreement with Andretti Global that expands the partnership and formally recognizes Zapata AI as Andretti's official AI Partner. The Andretti expansion will contribute to significant, sequential quarter-over-quarter bookings growth for Zapata AI, and is one of numerous customer growth opportunities Zapata is pursuing in financial services, telecom, manufacturing, defense, logistics and other industries. The new engagement expands Zapata AI's work with Andretti's engineering, operations, and race strategy teams with the goal of delivering significant innovation and operational efficiencies across Andretti's global presence in multiple racing series, while helping build a foundation for expansion to future series. "We're proud to expand our long-term commitment in support of our strategic partners at Andretti Global, as they maintain their competitive edge on the track, and as they expand their global footprint into future racing series," said Christopher Savoie, co-founder and CEO of Zapata AI. "The work we're doing with Andretti is a clear demonstration of the impact Industrial Generative AI can deliver across industries."

08:09 EDT Axcelis announces multiple shipments of the Purion Power Series systems - Axcelis Technologies announced multiple shipments of the Purion Power Series ion implanter systems to leading silicon carbide, or SiC, power device chipmakers worldwide. The shipments, all shipped in the first quarter, included the Purion H200 SiC high current, the Purion XE SiC high energy and the Purion M SiC medium current implanters. The 150mm and 200mm systems will be used in high volume production of power devices supporting automotive, industrial, energy, and other power intensive applications.

08:08 EDT Microchip announces new integrated actuation power solution - The aviation industry's requirements for the latest, most efficient and lowest-emission aircraft is propelled by an overarching goal towards sustainability and decarbonization. To satisfy these goals, aviation power systems developers are transitioning to electric actuation systems as the trend towards More Electric Aircraft continues to grow. To provide the aviation industry with a comprehensive electric actuation solution, Microchip Technology announces a new integrated actuation power solution that combines companion gate driver boards with our expansive Hybrid Power Drive modules in silicon carbide or silicon technology with a power range of 5 kVA to 20 kVA.

08:06 EDT Brainsway expands Deep TMS access in Israel - BrainsWay announced the further expansion of access to its Deep TMS treatment in Israel. BrainsWay has steadily increased its presence in the country with 11 recent system installations, and this momentum has been driven in part by a 45% increase in reimbursement rates. The Company expects to have additional Deep TMS systems installed in Israel by the end of 2024. "BrainsWay continues to make significant strides in expanding its international footprint, and it is extremely meaningful for us to be able to offer our life altering Deep TMS therapy to mental health patients across Israel," said Hadar Levy, Chief Executive Officer of BrainsWay. "Following recent events in the country, serious mental health conditions are on the rise, and it is profoundly important to us that Deep TMS be made available to as many patients as possible," concluded Levy.

08:04 EDT BranchOut Food announces sale of senior secured promissory notes - BranchOut Food has completed the sale of $225,000 of Senior Secured Promissory Notes and Warrants to purchase an aggregate of 56,250 shares of the Company's common stock. Each Warrant is exercisable for a ten-year period at an exercise price of $2.00 per share. The Company has board approval to borrow up to $2,000,000 of Notes. The current balance of Notes after this close is $625,000. The proceeds from this transaction are earmarked for working capital to fulfill orders throughout 2024, as well as capital expenditures on new dehydration equipment, which are necessary to meet the increasing customer demand projected for 2025 and beyond. The Company believes that the completion of this financing will provide it with the necessary resources to execute on its growth strategy, substantial momentum in new orders, and drive long-term shareholder value. The sale was made to a group of seven investors pursuant to a First Amendment to Subscription Agreement dated April 15-16, 2024. The transaction was conducted in accordance with Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder. The Notes mature on the earlier of December 31, 2024, or the occurrence of a Qualified Subsequent Financing or Change of Control, and bear interest at a rate of 15% per annum. The Notes are secured by liens on substantially all of the Company's assets pursuant to the terms of a Security Agreement entered into by the Company on January 10, 2024, in favor of holders of the Notes. In connection with the transaction, the Company also increased the aggregate principal amount of Notes available to be sold from time to time under the Subscription Agreement from $400,000 to $2,000,000, and increased the number of shares of common stock of the Company available to be issued under Warrants sold from time to time under the Subscription Agreement from 100,000 to 600,000. The current balance of Notes upon this close is $625,000.

08:03 EDT Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer - Stoke Therapeutics announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome.

08:03 EDT Sage Therapeutics down 19% at $12.60 after announcing dalzanemdor Phase 2 data

07:53 EDT Clearmind Medicine enters licensing agreement with Yissum Research - Clearmind Medicine announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant step in harnessing generation 3.0 psychedelic compounds, methods of their preparation, and uses thereof in the treatment of addiction and mental disorders. Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company's innovative portfolio in addiction and mental health treatments.

07:38 EDT Pedevco provides update on Permian Basin wells - PEDEVCO provided an operational update on its three newly drilled and completed horizontal San Andres wells in its Permian Basin Asset as follows: The Company drilled and completed three horizontal San Andres wells in its core Chaveroo Field in the Permian Basin with its strategic partner Evolution Petroleum Corporation. The wells were drilled in Q4 2023 and completed in January 2024, with first production commencing the last week of January 2024 on one well and early February 2024 for the other two wells. All three wells peaked at between approximately 300 to 375 gross barrels of oil equivalent per well in late February. The Company is pleased with the early production results, with the wells currently performing in line with expectations, but with shallower, better-than-expected declines which have yielded an average of over 750 BOEPD gross for the last 30 days. The Company is working with Evolution to plan the next phase of development over the coming months. As previously announced, in September 2023 the Company and Evolution entered into a Participation Agreement to jointly develop the Company's Chaveroo oilfield in the Northwest Shelf of southeastern New Mexico, a conventional oil-bearing San Andres field in the Permian Basin located in Chaves and Roosevelt Counties. The agreement covers approximately 16,000 gross acres with average working interest and net revenue interest of 100% and 82%, respectively, all currently owned by PEDEVCO. Evolution has farmed-in for a 50% WI in these initial three wells, and will farm-in for an average 50% WI in all future horizontal drilling locations on a block-by-block basis in which it elects to participate, with PEDEVCO remaining the operator with a working interest equal to Evolution in all wells that we jointly develop.

07:35 EDT Labrador Gold files NI43-101 technical report for Kingsway Project - Labrador Gold announced the completion and filing of an independent technical report prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects on its 100% owned Kingsway Gold Property located in Central Newfoundland. The technical report was completed by Tanya Tettelaar, P.Geo, M.Sc. who meets the requirements of an independent qualified person as described in National Instrument 43-101 and the companion Policy 43-101CP.

07:34 EDT SL Green Realty, Vornado announce 280 Park Avenue mezzanine loan repayment - SL Green Realty Corp. (SLG) and Vornado Realty Trust (VNO) modified and extended the $125.0 million mezzanine loan on 280 Park Avenue and subsequently repaid the loan for $62.5 million. Newmark advised the parties on the transaction.

07:33 EDT SL Green Realty, Vornado announce 280 Park Avenue mortgage loan refinancing - SL Green Realty Corp. (SLG) and Vornado Realty Trust (VNO) closed on a modification and extension of the $1.075 billion securitized mortgage on 280 Park Avenue. The modification extended the maturity date to September 2026, with the partnership's option to extend to a fully extended maturity date of September 2028. The interest rate was maintained through the fully extended maturity date at 1.78% over Term SOFR.

07:32 EDT Alterity announces presentations of data on Parkinson's Disease, MSA - Alterity Therapeutics announced that three posters were presented at the American Academy of Neurology 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company's work in Parkinson's disease and Multiple System Atrophy, including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial. Presentation Summaries: Title: A Phase 2 Study of ATH434, a Novel Inhibitor of alpha-Synuclein Aggregation, for the Treatment of Multiple System Atrophy. Results: The poster describes the baseline characteristics for the 65 evaluable participants from Alterity's ATH434-201 randomized, double-blind Phase 2 clinical trial, with a focus on baseline fluid biomarkers, neuroimaging and clinical data. The participants met the strict criteria designed to confirm that participants were diagnosed with early-stage MSA and had a mean of two years of motor symptoms. ATH434 is a potential disease modifying therapy based on its ability to redistribute excess labile iron without impairing normal iron storage, inhibit alpha-synuclein aggregation and reduce oxidative stress. Importantly, the increased iron levels in the trial participants were evident in multiple subcortical brain regions with two distinct patterns of iron accumulations observed. In addition, MSA participants with less than four years of motor symptoms have elevated plasma Neurofilament Light Chain levels at baseline which correlate significantly with disease severity. Title: Neurofilament Light Chain and Clinical Progression in Early Multiple System Atrophy. Results: The poster describes results from the bioMUSE Natural History Study in which changes in clinical severity of 15 patients across a span of 12 months were compared with plasma biomarkers with a goal of establishing meaningful correlations. The advancement of MSA is profoundly aggressive, highlighting the critical need for biomarkers to delineate its progression over time. Emerging interest surrounds the use of the fluid biomarker NfL, found in both cerebrospinal fluid and plasma, as an indicator of axonal damage in MSA. This fluid biomarker holds promise for measuring the extent of disease, tracking its progression, and forecasting the onset of clinical manifestations associated with MSA. In this observational study, the plasma NfL and CSF NfL were highly correlated, indicating that the more easily obtained plasma values have a meaningful relationship with brain pathology. Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA. These data suggest that NfL may be a marker of disease modification in studies of MSA. Title: Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in Hemiparkinsonian Macaques. Results: The presentation demonstrated that ATH434 treatment led to lower iron levels in the affected area of the brain, the substantia nigra, and improved motor performance and general function in monkeys with experimentally induced Parkinson's disease. At week 12, all 6 ATH434-treated macaques had stable or improving scores from Baseline while two of three vehicle-treated macaques did not demonstrate improvement. The improved general behavior was well-correlated with reduced motor impairment. These favorable parkinsonian outcomes observed in each of the ATH434-treated monkeys were also associated with increased levels of striatal synaptophysin, a protein marker that reflects functional connections between neurons, suggesting functional recovery of nerve endings in this critical motor pathway. These results support further investigation of ATH434 for the treatment of Parkinson's disease.

07:18 EDT Berry Global, Glatfelter announce regulatory milestone for spinoff - Berry Global (BERY) and Glatfelter (GLT) announced the achievement of a regulatory milestone in the proposed transaction involving the combination of a majority of Berry's Health, Hygiene and Specialties segment to include its Global Nonwovens and Films business, or HHNF, with Glatfelter, with the expiration of the required waiting period under the Hart-Scott-Rodino, or HSR, Antitrust Improvements Act. As previously announced on February 7, Berry and Glatfelter entered into a definitive agreement under which Berry will spin-off and merge its HHNF business with Glatfelter in a Reverse Morris Trust transaction. The transaction will create a leading, publicly-traded company in the specialty materials industry. The transaction is expected to close in the second half of calendar 2024 and is subject to approval by Glatfelter shareholders and completion of customary closing conditions.

07:16 EDT O-I Glass completes transformation of Zipaquira, Colombia manufacturing site - O-I Glass completed a major transformation of its Zipaquira, Colombia manufacturing site investing approximately $120 Million to upgrade the sustainability, flexibility, and productivity of the plant. This is consistent with O-I's sustainability strategy, the company's ongoing investments into plant upgrades, and aligned with its previously announced capital spending plan. A new furnace has been installed that incorporates well-proven oxy/fuel combustion and waste heat recovery technology. The investments are set to increase O-I's flexibility to serve strategic customers and emerging segments in the food and beverage sector and improve energy efficiency, lowering CO2 emissions by up to 15% per ton produced on the new furnace. In addition to the decarbonization impacts, the new technologies also reduce NOX emissions by up to 50 % compared to a traditional air fuel-fired furnace and allow for higher usage of recycled glass. At the Zipaquira plant, one of the largest O-I plants in Latin America with more than 700 employees, approximately 100 new jobs were created in conjunction with the new furnace along with a larger number of indirect jobs in the region.

07:14 EDT Poet Technologies retains Hybrid Financial, LFG for investor outreach efforts - POET Technologies has augmented its investor outreach through two new engagements with external service providers. POET has retained Hybrid Financial to connect the Company to a select group of technology investors identified from a database of over 1,400 buy-side funds in the United States and 200 in Canada that hold shares in companies that are valued less than $100 million, plus a larger number of broker-dealer firms and financial advisors. The agreement with Hybrid is for an initial period of 6-months starting April 1, 2024 and may be renewed automatically for successive 3-month periods thereafter. Hybrid will be paid a monthly fee of C$15,000, plus applicable taxes, during the Initial Term. Commencing later this month, LFG, an independent contractor based in the Greater Toronto Area, will provide advice, content development, and marketing services through social media channels and on-line media and newsletter placements for the Company. The agreement includes an initial payment of $25,000 with an option to increase at the Company's discretion. Neither Hybrid nor LFG Equities currently hold shares in POET, and both have agreed to comply with all applicable securities laws and the policies of the TSX Venture Exchange in providing the Services.

07:10 EDT Tilray announces series of music festivals, celebrations for 4/20 - Tilray Brands announces a series of 420-events, celebrations, and environmental initiatives in the U.S. across Tilray's craft beer brands. Celebrating community, craft brewing excellence, and environmental stewardship, Tilray's craft brands, including SweetWater Brewing, Blue Point Brewing, Redhook Brew, 10 Barrel Brewing, Breckenridge Brewery, and Montauk Brewing, are hosting memorable events and launching specialty brews that reflect each brand's commitment to sustainability, creativity, and the spirited celebration of 420.

07:08 EDT Luminosity partners with Amazon for Rocket League Invitational Tournament - Enthusiast Gaming Holdings (EGLXF) announced that in partnership with Amazon (AMZN), its esports team, Luminosity will be hosting a Rocket League invitational event featuring North America's top-ranked teams and players to promote Amazon Prime. The two-day invitational event will be hosted by Sean 'Spaceman' Rogers and Jack 'Corelli' Collier and feature eight of the top professional North American Rocket League teams, including Luminosity's very own, as they compete to earn a $15,000 prize pool on April 30th and May 1st. Throughout the tournament, players will be able to use unlimited boost as part of the 'Prime Boost Advantage' while Luminosity will run dynamic overlays that encourage fans to boost their shopping and streaming experience with Amazon. To promote the event, participants will be actively posting on their personal social media accounts and streaming their perspective of the event. In addition, the Company is pleased to announce that its previously announced sale of select non-core and non-profitable casual gaming assets has closed. Among the assets included as part of the divestment were Shockwave, LittleBigSnake, MathGames.com, and TypeRacer.com. Further details on the transaction can be found in the Company's press release dated April 1, 2024.

07:07 EDT GXO Logistics, Daikin Industries announce opening of new Midlands warehouse - Daikin (DKILY) has announced the opening and commencement of outbound deliveries from its new Midlands warehouse in Daventry, in partnership with its logistics partner GXO (GXO), the world's largest pure-play contract logistics provider. Located in the heart of the U.K. logistics "golden triangle" in the Midlands, Daikin, together with GXO, have jointly invested over GBP 4 million to consolidate their operations into one facility. "We're delighted to support Daikin's growth in the U.K.", said Clare Davies, Managing Director of GXO Direct. "Our flexible, scalable GXO Direct shared warehousing helped support Daikin's growth to the stage where they are ready to move to their own warehouse solution. This new dedicated facility provides them with the flexibility and space they need to continue their business growth. GXO Direct shared warehousing is particularly suited to helping companies, including those in the heating and ventilation sector, grow their operations in an efficient manner."

07:06 EDT Bowman Consulting acquires MEP/FP firm Moore, sees immediate accretion - Bowman Consulting Group announced the acquisition of Moore Consulting Engineers , a mechanical, electrical, plumbing, and fire protection or MEP/FP, engineering firm based in Shamong, New Jersey. "Moore Consulting Engineers adds additional depth to our growing MEP and fire protection practices," said Gary Bowman, chairman and CEO of Bowman. "Jeff has built a great business over the past 21 years, and we are proud to be partnering with the entire Moore team as they move to the next chapter in their story. Their focus on LEED standards brings additional expertise to our portfolio of services, and I am confident they will integrate quickly and add value immediately." Financed with a combination of cash, seller notes, and equity, the acquisition falls within previously discussed target multiples and operating metric ranges. The company anticipates the acquisition will initially operate at an annualized net service billing run rate of approximately $4.0M and be immediately accretive. More detailed information on M&A activities, pipeline, and guidance updates are provided in connection with scheduled quarterly and annual communications.

07:04 EDT PyroGenesis enters agreement with mining supply company to explore plasma use - PyroGenesis Canada has entered into an agreement with a global leader in mining parts manufacturing to assess the applicability of PyroGenesis' fully electric plasma torches in the Client's metal cast houses. As the Company announced in its recent year-end earnings report, the Company had been in advanced discussions with the Client. The Client's name shall remain anonymous for competitive and confidentiality reasons. The Client, a billion-dollar entity with facilities on five continents, is one of the world's largest manufacturers of products that serve the mining and defense industries, amongst others. This agreement outlines the steps necessary to generate relevant data from a PyroGenesis plasma torch test, in anticipation of having it possibly replacing burners in the Client's legacy system that emits significant CO2. The Client, a significant carbon emitter, hopes this initiative will support its energy-transition/decarbonization goals and address an emissions problem facing the industry as a whole. PyroGenesis' engineering team are confident that they will be able to propose a solution to this problem. The test contemplated by this initial engagement should be completed within the next 10 weeks. Should the test prove successful, it is expected that the Client will move to step 2, which envisions producing a complete plasma torch-based system on-site to replace an existing fossil fuel burner. Such a system would include a PyroGenesis plasma torch as well as the accompanying manipulation/handling components. Step 2 would take approximately 6 months depending on the delivery time of a specific long lead item and generate approximately $500,000-$1,000,000 in revenues to PyroGenesis. It is estimated that the industry has thousands of such burners in operation world-wide. The Company's development of plasma torches is part of the Company's three-tiered solution ecosystem that aligns with economic drivers that are key to global heavy industry. The use of plasma torches within manufacturing facilities is part of the Energy Transition & Emission Reduction tier, where fuel switching to the Company's electric-powered plasma torches helps heavy industry reduce fossil fuel use and greenhouse gas emissions.

07:01 EDT U.S. Bancorp cuts FY24 NII view to $16.1B-$16.4B from $16.6B - Sees mid single digit growth in noninterest income in FY24 vs. FY23. Sees noninterest expense $16.8B or less in FY24 vs. previous expectations of $17B.

06:50 EDT U.S. Bancorp reports Q1 net interest margin 2.70% vs. 3.10% last year - In Q1: Noninterest income increased 7.7% year-over-year and decreased 1.4% on a linked quarter basis, as adjusted for notable items. Noninterest expense decreased 2.7% year-over-year and 0.2% on a linked quarter basis, as adjusted for notable items. Average total loans decreased 0.5% and average total deposits increased 0.1% on a linked quarter basis. Return on tangible common equity of 17.4%, return on average assets of 0.93%, and efficiency ratio of 62.5%, as adjusted for notable items. CET1 capital ratio of 10.0% at March 31, 2024, compared with 9.9% at December 31, 2023.

06:45 EDT Huize parners with Aviva-COFCO Life Insurance to launch Fu Man Jia insurance - Huize Holding announced that it has partnered with Aviva-COFCO Life Insurance to launch "Fu Man Jia", a customized participating whole life insurance product. "Fu Man Jia" stands out with three key features are: astable value growth with long-term potential returns: a guaranteed return on a compound basis of 2.5% with additional non-guaranteed annual dividend; a low threshold with high dividend flexibility: policy available to customers from 30 days after birth to 70 years old, with options in receiving dividend payout, including cash payment, dividends on deposit, premium reduction, or purchasing paid-up additional insurance; and an enhanced flexibility with premium payment terms of single upfront payment or annual payments ranging from 3 years to 15 years.

06:33 EDT Trilogy Metals provides update on Ambler Access Project - Trilogy Metals provided an update on the Ambler Access Project - the proposed 211-mile, industrial-use-only road from the Upper Kobuk Mineral Projects to the Dalton Highway that would enable the advancement of exploration and development at the Ambler Mining District, home to some of the world's richest known copper-dominant polymetallic deposits. On April 16, the Alaska Industrial Development and Export Authority, or AIDEA, issued a press release in response to media reports indicating the Department of Interior plans to block access to the Ambler Mining District by issuing a "no action" decision. In its press release, AIDEA strongly urges the Department of Interior to comply with federal law and the promises made at statehood to allow access to state lands and minerals for the Ambler Access Road Project.

06:30 EDT Citizens Financial sees FY24 net interest income down ~2% - Sees FY24: Noninterest income up ~3%-4%; noninterest expense stable to down slightly; net charge-offs ~50 bps; ACL will continue to benefit from non-core run off; CET1 ratio ~10.5%; tax rate ~21%. Broadly reaffirms FY24 outlook provided in January. Updated key rate assumptions: 25 bp Fed rate cut in July and December with YE2024 Fed Funds target of 5%. Comments taken from investor presentation slides for Q1 earnings conference call.

06:21 EDT Novartis announces data from the ALITHIOS study of Kesimpta - Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta treatment for up to six years in recently diagnosed treatment-naive people living with relapsing multiple sclerosis. These efficacy outcomes included 44% fewer relapses; 96.4% and 82.7% reductions in MRI lesions, respectively; and 24.5% and 21.6% fewer 3- and 6-month confirmed disability worsening events, respectively, versus those who switched to Kesimpta from teriflunomide. Study Results: In the first analysis, the low annualized relapse rate experienced by recently diagnosed treatment-naive people living with RMS receiving continuous Kesimpta during the core Phase III trials was further reduced in the ALITHIOS open-label extension study, from 0.104 to 0.050, corresponding to an adjusted ARR of one relapse per 20 years. Rates of 3- and 6-month progression independent of relapse activity with first-line Kesimpta were also lower versus switch. In RDTN people living with RMS initially randomized to teriflunomide, improvements across several efficacy outcomes were seen after switching to Kesimpta, including significant reductions in ARR and in MRI lesion activity, and rapid increase in rates of NEDA-3. However, rates of 3- and 6-month CDW events remained higher compared to patients receiving continuous Kesimpta, indicating that the efficacy benefit of first-line Kesimpta on delaying disability worsening was not fully achieved in the switch group. Across both continuous and switch groups, nine out of 10 participants achieved NEDA-3 at Year 6. Similar results were seen in the second analysis, which looked at the overall ALITHIOS population. Data showed sustained efficacy of continuous Kesimpta up to six years, including low ARR, suppression of MRI lesion activity, sustained reduction of 6-month CDW events, lower rates of 6-month PIRA, and sustained high rates of NEDA-3. At Year 6, NEDA-3 status was achieved in nine out of 10 participants in both the continuous and switch groups. The study also found that treatment with Kesimpta for up to six years was well-tolerated with no unexpected safety signals identified. The rates of adverse events, serious AEs, serious infections, and malignancies remained stable with no increased risks over six years.

06:17 EDT Roche announces data from its Phase III OCARINA II study of OCREVUS - Roche announced data from the Phase III OCARINA II study of OCREVUS. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis which reinforce the potential benefits of this investigational formulation. The data will be presented as an oral presentation at the 76th American Academy of Neurology Annual Meeting taking place April 13-18 in Denver. Updated, longer-term results showed that OCREVUS SC injection resulted in near-complete suppression of relapse activity and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing lesions and no new/enlarging T2 lesions. Additionally, in exploratory patient reported outcome measures patients reported a high level of satisfaction and convenience with OCREVUS SC injection. Additional data continued to show that the safety profile of OCREVUS SC injection was consistent with the well-established safety profile of OCREVUS IV infusion. No new safety signals were identified for OCREVUS SC. The most common adverse events in the OCREVUS SC group were injection reactions, including erythema, pain, swelling and pruritus, all of which were either mild or moderate and none of which led to treatment withdrawal.

06:13 EDT GSK announces results from its EAGLE-1 phase III trial for gepotidacin - GSK announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults. These results will be presented on 30 April 2024 at the European Society of Clinical Microbiology and Infectious Diseases, ESCMID, Global in Barcelona, Spain. The results from EAGLE-1 are based on a primary endpoint of microbiological response at the Test-of-Cure visit 3-7 days after treatment. The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment regimen for gonorrhoea. The safety and tolerability profile of gepotidacin in the EAGLE-1 trial was consistent with results seen in phase I and II trials. The most commonly reported adverse events in gepotidacin subjects were gastrointestinal. All AEs were mild or moderate except for one severe, unrelated event in each treatment arm and one unrelated serious event in the gepotidacin arm.

06:03 EDT KBR technology selected for Fortescue project in Norway - KBR announced it has signed a contract to provide its green ammonia technology, K-GreeN, for Fortescue's Holmaneset green energy project in Norway. Under the terms of the contract, KBR will provide technology license, proprietary engineering design, and FEED support engineering services for the 675 metric tonnes per day grassroots green ammonia plant in Norway.

05:36 EDT Allegiant Travel flight attendants ratify new labor contract - Allegiant announced that the company and the Transport Workers Union of America, AFL-CIO Local 577, representing Allegiant's flight attendants, have ratified a new five-year agreement with immediate wage increases ranging from 20% to 41.2%. The tentative agreement was ratified by Allegiant flight attendants with an 89% approval vote and 97% of members voting. The TWU Local 577 represents more than 1,700 Allegiant flight attendants. Flight attendants received an average pay increase of 25% upon the contract's ratification. Flight attendants at the top of the wage scale receive a 41.2% wage increase. In addition to the wage increases, the contract includes many other enhancements such as improved pay overrides. The company said, "In addition to pay raises, the new contract provides several quality of life improvements for TWU 577 members. One major improvement is the greater "duty rig," which will increase the amount of time flight attendants are paid for being on duty. The contract also contains an improved 401k match, a cap on healthcare cost share increases, and other insurance improvements. In addition to the average 25 percent wage increase upon ratification, all flight attendants will receive an hourly pay increase of 3 percent each year, for a combined 41 percent average wage increase over the life of the contract. In addition to wage increases, the Local 577 members will receive a combined $10 million lump sum bonus. Flight attendants will receive a minimum $1,500 lump sum bonus or a bonus of approximately $1,013 per year of service, whichever is greater. The parties' previous collective bargaining agreement became amendable on December 21, 2022, and Allegiant and the TWU were able to secure the new contract in just over a year and a half of bargaining by building on their strong positive working relationship."

05:20 EDT Genentech reports data from OCARINA II study of Ocrevus - Genentech, a member of Roche, announced data from the Phase III OCARINA II study of Ocrevus, an investigational twice-yearly, 10-minute subcutaneous, or SC, injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis which reinforce the potential benefits of this investigational formulation. Treatment with Ocrevus SC led to rapid and sustained B-cell depletion in the blood. The data will be presented as an oral presentation at the 76th American Academy of Neurology, or AAN, annual meeting taking place April 13-18 in Denver and has been recognized as an abstract of distinction by the AAN scientific committee. Updated, longer-term results showed that Ocrevus SC injection resulted in near-complete suppression of relapse activity and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing lesions and no new/enlarging T2 lesions. These lesion types are markers of active inflammation and burden of disease, respectively. Additionally, in exploratory patient reported outcome measures patients reported a high level of satisfaction and convenience with Ocrevus SC injection. Additional data continued to show that the safety profile of Ocrevus SC injection was consistent with the well-established safety profile of Ocrevus IV infusion. No new safety signals were identified for Ocrevus SC. The most common adverse events in the Ocrevus SC group were injection reactions, including erythema, pain, swelling and pruritus, all of which were either mild or moderate and none of which led to treatment withdrawal. A total of seven serious AEs were experienced by three and four patients in the Ocrevus SC injection and IV infusion groups, respectively. The twice-yearly, 10-minute SC injection has the potential to expand the usage of Ocrevus to treatment centers without IV infrastructure or with IV capacity limitations. Data from the Phase III OCARINA II trial were submitted to health authorities around the world following the first presentation of these results during ECTRIMS-ACTRIMS 2023. Both the European Medicines Agency, or EMA, and FDA have accepted Genentech's submissions, with a target decision date of mid-2024 for the EMA and September 2024 for the FDA.

05:12 EDT XPeng, Volkswagen enter framework agreement on E/E architecture technical pact - XPeng (XPEV) and the Volkswagen (VWAGY) announced that XPeng and the Volkswagen (VWAGY) have entered into a framework agreement on technical collaboration with respect to Electrical/Electronic architecture. XPeng's in-house developed E/E Architecture is core to its vertically integrated full-stack software and hardware technologies. It allows software including ADAS and Connectivity OS to decouple from the underlying hardware and vehicle platforms, achieving fast iteration of software across platforms. XPeng's latest generation of E/E Architecture adopts central computing and domain controller-based architecture which provides high-performance in-car computing environment and competitive cost structure. The E/E Architecture supports Gigabit Ethernet high-speed data transmission between the central domain and ADAS domain controllers. The E/E Architecture also supports highly efficient whole-vehicle OTA for both customers' vehicles and vehicles at the end of manufacturing lines. Under the E/E Architecture technical collaboration, XPeng and the Volkswagen Group, will jointly develop and integrate XPeng's latest generation of E/E Architecture to Volkswagen's China Main Platform in China. The jointly developed E/E Architecture is expected to equip Volkswagen brand electric vehicles produced in China from 2026.